Dear Shareholders,

On behalf of the Board of Directors of DanCann Pharma, I write to you at a time of important organizational change and strategic realignment for our Company.

Leadership Transition

As part of this transition, our founder and long-standing Chief Executive Officer, Mr. Jeppe Krog Rasmussen, has resigned from his position in order to pursue new challenges. Jeppe founded DanCann Pharma with a clear mission: to bring cannabinoid-based medicines into the lives of patients who need them. Under his leadership, the Company navigated its formative years, secured regulatory approvals, established production infrastructure, and positioned itself as a trusted operator within a complex and highly regulated industry. On behalf of the Board, I extend our sincere gratitude to Jeppe for his vision, relentless commitment, and many years of service to DanCann Pharma.

In the interim period, I will assume the position of Chief Executive Officer, as appointed by the Board of Directors, with the intention of nominating Mr. Peter Hauberg Søndergaard, formerly Chief Financial Officer of DanCann Pharma, as the new Chief Executive Officer, during the upcoming months. Peter brings with him deep financial expertise and proven operational discipline. As CEO, Peter will focus on guiding the Company through the delisting process, strengthening operational efficiency, and executing our long-term growth plan under the Maturity2028 strategy. His leadership will emphasize disciplined capital allocation and a renewed focus on profitability and sustainable value creation. The Board welcomes Peter in his new capacity and looks forward to his leadership in the next chapter of DanCann Pharma’s journey.

In order to ensure a smooth transition, Jeppe will during this period continue to serve in an advisory capacity to support Peter in his new role as Chief Executive Officer.

Voluntary Delisting from Spotlight Stock Market

As previously communicated, the Board of Directors has resolved to apply for a voluntary delisting of the Company’s shares from Spotlight Stock Market, pursuant to Section 6.3 of the Spotlight Stock Market Regulations, subject to approval by the general meeting. The delisting will be carried out in accordance with the Swedish Stock Market Self-Regulation Committee’s Rules on Delisting of Shares at the Initiative of the Issuer (“Regler om avnotering av aktier på emittentens initiativ”), effective 1 September 2025, applicable to foreign companies listed on Spotlight.

The decision follows a careful evaluation of the Company’s position, taking into account the following:

1. Disproportionate cost and administrative burden

Maintaining a listing on Spotlight entails significant recurring expenses and compliance obligations. For a company of DanCann Pharma’s current size and resource base, these obligations have become disproportionate, diverting attention and capital away from operations and business development.

2. Strategic realignment and reduced capital needs

Since 2023, DanCann Pharma has repositioned its strategy and reduced its capital requirements compared to the assumptions underpinning the original listing. Current funding needs are better aligned with private capital markets, where long-term, strategically aligned investors can be engaged more effectively.

3. Limited investor interest and liquidity

The Company’s modest market capitalization and low share liquidity have negatively affected investor perception and contributed to trading volatility. This has constrained the Company’s ability to attract institutional or well-capitalized investors and limited practical access to funding in the public markets.

Taken together, these factors have led the Board to conclude that the benefits of a continued listing no longer outweigh the costs and limitations associated with it. A voluntary delisting will enable DanCann Pharma to allocate resources more efficiently, sharpen operational focus, and secure capital through private channels better suited to its profile and strategic ambitions.

Looking Ahead

The Board firmly believes that these measures – together with the leadership transition – are in the best interest of the Company and its shareholders. Our priority remains to build a resilient, financially sustainable business that delivers on its long-term commitments under Maturity2028.

Based on these factors – both the organizational restructuring and the delisting, as well as the ongoing efforts to divest BP1 (the company’s production facilities) – the Company intends to continue pursuing its path towards future profitability supported by these changes.

On behalf of the Board, I thank you for your continued trust and support as we take these decisive steps to secure the future of DanCann Pharma.

Yours sincerely,

Carsten Trads
Chairman of the Board
DanCann Pharma A/S

For further information, please contact:

Carsten Trads, Chairman

E-mail: ctr@dancann.com

About DanCann Pharma A/S

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm.

For more information, please visit: www.dancann.com

Forward-looking-statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.